ARIAD Pharmaceuticals, Inc. ARIA today announced the presentations on ponatinib, its investigational BCR-ABL inhibitor, that will take place at the 54th Annual Meeting of the American Society of Hematology (ASH) being held in Atlanta, December 8 to 11, 2012. Updated and new results on the PACE trial will be featured in five presentations – two oral and three posters.
PACE Trial: 12-Month Follow Up in Chronic Phase Patients |
||
Title: | A Pivotal Phase 2 Trial of Ponatinib in Patients with Chronic Myeloid Leukemia (CML) and Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ALL) Resistant or Intolerant to Dasatinib or Nilotinib, or with the T315I BCR-ABL Mutation: 12-Month Follow-up of the PACE Trial | |
Oral Session: | 632. Chronic Myeloid Leukemia - Therapy I Session | |
Date & Time: | Sunday, December 9, 2012, 4:30 p.m. | |
Abstract No.: | 163 | |
Presenter: |
Jorge E. Cortes, M.D. (The University of Texas MD Anderson Cancer Center) |
|
Location: | Georgia World Congress Center, A411-A412 | |
PACE Trial: Efficacy and Safety in Advanced Phase Patients |
||
Title: | Efficacy and Safety of Ponatinib in Patients with Accelerated Phase or Blast Phase Chronic Myeloid Leukemia (AP-CML or BP-CML) or Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL): 12-Month Follow-up of the PACE Trial | |
Oral Session: | 632. Chronic Myeloid Leukemia - Therapy II Session | |
Date and Time: | Tuesday, December 11, 2012 at 8:00 a.m. | |
Abstract No.: | 915 | |
Presenter: | Hagop M. Kantarjian, M.D. (The University of Texas MD Anderson Cancer Center) | |
Location: | Georgia World Congress Center, A411-A412 | |
PACE Trial: Results According to Prior Tyrosine Kinase Inhibitor Therapy |
||
Title: | Efficacy and Safety of Ponatinib According to Prior Approved Tyrosine Kinase Inhibitor (TKI) Therapy in Patients with Chronic Myeloid Leukemia in Chronic Phase (CP‐CML): Results from the PACE Trial | |
Poster Session: | 632. Chronic Myeloid Leukemia - Therapy: Poster III | |
Date & Time: | Monday, December 10, 2012, 6:00 – 8:00 p.m. | |
Abstract No.: | 3749 | |
Presenter: | Dong-Wook Kim, M.D., Ph.D. (Mary's Hospital, The Catholic University of Korea) | |
Location: | Georgia World Congress Center, Hall B1-B2 | |
PACE Trial: Molecular Response Data |
||
Title: | Molecular Responses with Ponatinib in Patients with Philadelphia Chromosome Positive (Ph+) Leukemia: Results From the PACE Trial | |
Poster Session: | 632. Chronic Myeloid Leukemia - Therapy: Poster III | |
Date & Time: | Monday, December 10, 2012, 6:00 – 8:00 p.m. | |
Abstract No.: | 3763 | |
Author: | Andreas Hochhaus, M.D., University Medical Center Jena in Germany | |
Location: | Georgia World Congress Center, Hall B1-B2 | |
PACE Trial: Multivariate Analysis of Parameters |
||
Title: | Multivariate Analyses of the Clinical and Molecular Parameters Associated with Efficacy and Safety in Patients with Chronic Myeloid Leukemia (CML) and Philadelphia Chromosome‐Positive Acute Lymphoblastic Leukemia (Ph+ ALL) Treated with Ponatinib in the PACE Trial | |
Poster Session: | 632. Chronic Myeloid Leukemia - Therapy: Poster III | |
Date & Time: | Monday, December 10, 2012, 6:00 – 8:00 p.m. | |
Abstract No.: | 3747 | |
Presenter: | Michael Mauro, M.D. (Oregon Health & Science University) | |
Location: | Georgia World Congress Center, Hall B1-B2 | |
Phase 1 Trial: Long-term Results |
||
Title: | Long-Term Anti-Leukemic Activity of Ponatinib in Patients with Philadelphia Chromosome-Positive Leukemia: Updated Results from an Ongoing Phase 1 Study | |
Poster Session: | 632. Chronic Myeloid Leukemia - Therapy: Poster III | |
Date & Time: | Monday, December 10, 2012, 6:00 – 8:00 p.m. | |
Abstract No.: | 3743 | |
Presenter: | Michael Deininger, M.D., Ph.D. (University of Utah School of Medicine Huntsman Cancer Institute) | |
Location: | Georgia World Congress Center, Hall B1-B2 | |
About ARIAD
ARIAD Pharmaceuticals, Inc. is an emerging global oncology company focused on the discovery, development and commercialization of medicines to transform the lives of cancer patients. ARIAD's approach to structure-based drug design has led to several internally discovered, molecularly targeted medicines for drug-resistant or difficult-to-treat cancers, including chronic myeloid leukemia and non-small cell lung cancer. For additional information, visit http://www.ariad.com or follow ARIAD on Twitter (@ARIADPharm).
ARIAD Pharmaceuticals, Inc.
For Investors
Kendra Adams,
617-503-7028
Kendra.adams@ariad.com
or
For
Media
Liza Heapes, 617-621-2315
Liza.heapes@ariad.com
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.